Emerging drugs for hemophilia A: insights into phase II and III clinical trials

References

• Mehta P, and Reddivari AKR. Hemophilia. 2021 Jun 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. [PubMed: 31869071]
   Google Scholar
• Biggs R. Haemophilia. Proc R Soc Med. 1969. Sep;62(9):913–914. [PubMed: 4241884].
   PubMedGoogle Scholar
• Schramm W. The history of haemophilia – a short review. Thromb Res. 2014. Nov;134(1):4–9. [PubMed: 24513149]
   PubMedGoogle Scholar
• Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost. 2014. Jul;40(5):571–576. [PubMed: 24911674]
   PubMed Web of Science ®Google Scholar
• Ingram GI. The history of haemophilia. J Clin Pathol. 1976. Jun;29(6):469–479. [PubMed: 780375].
   PubMedGoogle Scholar
• Kasper CK. Judith Graham Pool and the discovery of cryoprecipitate. Haemophilia. 2012. Nov;18(6):833–835. [PubMed: 23106944].
   PubMed Web of Science ®Google Scholar
• Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia. 2004. Jan;10(1):1–8 [PubMed: 14962214].
   PubMed Web of Science ®Google Scholar
• Wilde J, Teixeira P, Bramhall SR, et al. Liver transplantation in haemophilia. Br J Haematol. 2002. Jun;117(4):952–956 [PubMed: 12060136].
   PubMed Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Data and demographics committee of the world federation of hemophilia. establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019. Oct 15;171(8):540–546. [PubMed: 31499529]
   PubMed Web of Science ®Google Scholar
• Hay CR, Palmer B, Chalmers E, et al. United kingdom haemophilia centre doctors’ organisation (UKHCDO). incidence of factor viii inhibitors throughout life in severe hemophilia a in the United Kingdom. Blood. 2011. Jun 9;117(23):6367–6370. [PubMed: 21471523]
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia. A Res Pract Thromb Haemost. 2018. Apr10;2(2):220–227. [PubMed: 30046724]
   PubMed Web of Science ®Google Scholar
• Witmer C, Young G. Factor VIII inhibitors in hemophilia a: rationale and latest evidence. Ther Adv Hematol. 2013 Feb;4(1):59–72. [PubMed: 23610614]
   PubMedGoogle Scholar
• Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017. Apr 17;6(4):46. [PubMed: 28420167]
   PubMed Web of Science ®Google Scholar
• Lillicrap D, Fijnvandraat K, Young G, et al.Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020. Apr;13(4):313–321. [PubMed: 32186928]
   PubMed Web of Science ®Google Scholar
• How YG. I treat children with haemophilia and inhibitors. Br J Haematol. 2019. Aug;186(3):400–408. [PubMed: 31069799]
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017. Aug 31; 377(9):809–818. [PubMed: 28691557]
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019. Dec 12; 134(24):2127–2138. [PMID: 31697801]
   PubMed Web of Science ®Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007. Sep 5; 5(9):1904–1913. [PubMed: 17723130]
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011. Nov 3;365(18):1684–1692. Erratum in: N Engl J Med. 2011 Dec 22;365(25):2441.[PubMed: 22047559]
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007. Aug 9;357(6):535–544. [PubMed: 17687129]
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al.Mannucci PM; ESPRIT study group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost. 2011. Apr 9;9(4):700–710. [PubMed: 21255253]
   PubMed Web of Science ®Google Scholar
• Young G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018. Oct23;2(20):2780–2782. [PubMed: 30352951]
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost.2003. Jul;1(7):1349–1355. [PubMed: 12871268]
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012. May 3;119(18):4108–4114. [PubMed: 22411872]
   PubMed Web of Science ®Google Scholar
• Arcieri R, Calizzani G, Candura F, et al. Recommendations for factor VIII product source to treat patients with haemophilia A. Blood Transfus. 2017. May;15(3):285. [PubMed: 28287386].
   PubMed Web of Science ®Google Scholar
• Arcieri R, Calizzani G, Candura F, et al. The increased demand for plasma-derived factor VIII in Italy. Blood Transfus. 2017. May;15(3):279–280. [PubMed: 27483485].
   PubMed Web of Science ®Google Scholar
• Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia. 2001. Jan;7(1):117–122. [PubMed: 11136393].
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia. 2010. Jan;16(1):33–46. [PubMed: 19845774]
   PubMed Web of Science ®Google Scholar
• Bird A, Isarangkura P, Almagro D, et al.Factor concentrates for haemophilia in the developing world. Haemophilia. 1998. Jul;4(4):481–485. [PubMed: 9873778]
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Cannavò A, Garagiola I, sippet study group, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018. Jan; 16(1):39–43. [PubMed: 29080391]
   PubMed Web of Science ®Google Scholar
• Fallon PG, Lavin M, O’Donnell JS. SIPPET: insights into factor VIII immunogenicity. J Thromb Haemost. 2018. Jan;16(1):36–38. [PubMed: 29080389]
   PubMed Web of Science ®Google Scholar
• Iorio A. Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development. Haemophilia. 2017. May;23(3):350–352. [PubMed: 28220559]
   PubMed Web of Science ®Google Scholar
• Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007. Apr;21(2):101–117. [PubMed: 17397761]
   PubMed Web of Science ®Google Scholar
• Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus. 2011. Oct;9(4):366–370. [PubMed: 21627925].
   PubMed Web of Science ®Google Scholar
• Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion. 2014. May;54(5):1406–1417. [PubMed: 24117799]
   PubMed Web of Science ®Google Scholar
• Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 2000. Jun;14(2):94–110. [PubMed: 11012252]
   PubMed Web of Science ®Google Scholar
• Collins PW, Chalmers E, Hart DP, et al. UK haemophilia centre doctors. diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK haemophilia centre doctors organization. Br J Haematol. 2013. Jan;160(2):153–170. [PubMed: 23157203]
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Mancuso ME, Warad D, et al. Central venous access device (CVAD) complications in haemophilia with inhibitors undergoing immune tolerance induction: lessons from the international immune tolerance study. Haemophilia. 2015. Sep;21(5):369–374. [PubMed: 26178581]
   Web of Science ®Google Scholar
• Jiménez-Yuste V, Oldenburg J, Rangarajan S, et al. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. Haemophilia. 2016. Nov;22(6):859–865. [PubMed: 27329267]
   PubMed Web of Science ®Google Scholar
• Kreuz W, Escuriola Ettingshausen C, Vdovin V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016. Jan;221:87–95. [PubMed: 26202305].
   PubMed Web of Science ®Google Scholar
• Rocino A, Cortesi PA, Scalone L, et al. European haemophilia therapy strategy board (EHTSB); European haemophilia therapy strategy board EHTSB. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European cohort (the ITER study). Haemophilia. 2016. Jan;22(1):96–102. [PubMed: 26278414]
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Jiménez‐Yuste V, Peiró‐Jordán R, et al. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF -containing plasma-derived FVIII concentrate. Haemophilia. 2014. Jan;20(1):83–91. [PubMed: 24354480]
   PubMed Web of Science ®Google Scholar
• Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009. Apr 16; 360(16):1618–1627. [PubMed: 19369668]
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Klukowska A, Pasi J, et al. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Ther Adv Hematol. 2019. Jun 26; 10:2040620719858471. [PubMed: 31263528]
   Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013. Jan 17;368(3):231–239. [PubMed: 23323899]
   PubMed Web of Science ®Google Scholar
• Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood. 2014. Nov 27;124(23):3389–3397. [PubMed: 25339360]
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014. Nov 27;124(23):3398–3408. [PubMed: 25253771]
   PubMed Web of Science ®Google Scholar
• Medzihradszky KF, Besman MJ, Burlingame AL. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem. 1997. Oct 1;69(19):3986–3994. [PubMed: 9322435]
   PubMed Web of Science ®Google Scholar
• Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood. 2016. Jul 7;128(1):104–109. [PubMed: 27207787]
   PubMed Web of Science ®Google Scholar
• Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. 2009. Sep;11(3):424–431. [PubMed: 19499345]
   PubMed Web of Science ®Google Scholar
• Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013 May 16;4:49–56. [PubMed: 23700376]
   PubMedGoogle Scholar
• von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia. 2017 Jul;23(4):566–574. [PubMed: 28370896]
   PubMed Web of Science ®Google Scholar
• Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012. Mar 29; 119(13):3024–3030. [PubMed: 22246033]
   PubMed Web of Science ®Google Scholar
• Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. [PubMed: 23537723]. Thromb Res. 2013 Mar;131(2):2–6.
   Google Scholar
• Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013 Jan;19(1):11–20. [PubMed: 22913770]
   PubMed Web of Science ®Google Scholar
• Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies?. Expert Opin Emerg Drugs. 2015;20(4):531–536. [PubMed: 26583759].
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012. Mar 29;119(13):3031–3037. [PubMed: 22223821]
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. A-LONG investigators. phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014. Jan 16; 123(3):317–325. [PubMed: 24227821]
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015. Jun;13(6):967–977. [PubMed: 25912075].
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016. Jan;22(1):72–80. [PubMed: 26218032].
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015. Aug27; 126(9):1078–1085. [PubMed: 26157075]
   PubMed Web of Science ®Google Scholar
• Mullins ES, Stasyshyn O, Alvarez-Román MT, et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017. Mar;23(2):238–246. [PubMed: 27891721].
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013. Apr;11(4):670–678. [PubMed: 23398640]
   PubMed Web of Science ®Google Scholar
• Aledort L, Mannucci PM, Schramm W, et al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019. Nov;17(6):479–486. [PubMed: 31846611].
   PubMed Web of Science ®Google Scholar
• Königs C, Ozelo MC, and Dunn A, et al. Final results of PUPs A-LONG study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A. [abstract] Res Pract Thromb Haemost. 2020 4 (Suppl 1). ;
   Google Scholar
• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tuddenham EG. The hemophilias– from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779.
   PubMed Web of Science ®Google Scholar
• Walsh CE, Soucie JM, Miller CH. United States hemophilia treatment center network. impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–405.
   PubMed Web of Science ®Google Scholar
• Young G. New approaches in the management of inhibitor patients. Acta Haematol. 2006;115(3–4):172–179.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017. Dec 7;130(23):2463–2468. [PubMed: 29042366]
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012. Oct; 18(10): 1570–1574. [PubMed: 23023498]
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017. Jun 28; 117(7):1348–1357. [PubMed:28451690]
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811–822. [PubMed:30157389].
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun;6(6):295–305. [PubMed: 31003963].
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016 May 26;374(21):2044–2053. [PubMed: 27223146].
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Marquez-Casas E, Phei Wee C, et al. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. [PubMed: 33245833]. Haemophilia. 2021 Jan;27(1):164–172.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. rAHF-PFM clinical study group. plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008. Aug;6(8):1319–1326. [PubMed: 18503631].
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. the recombinate previously treated patient study group. Thromb Haemost. 1997. Apr;77(4):660–667. [PubMed:9134639]
   PubMed Web of Science ®Google Scholar
• Fijnvandraat K, Berntorp E, Ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost. 1997. Feb;77(2):298–302. [PubMed: 9157585].
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013. Apr;11(4):670–678. [PubMed: 23398640]
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94–9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014. Apr;12(4):488–496. [PubMed: 24843882]
   PubMed Web of Science ®Google Scholar
• Terraube V, O’Donnell JS, Jenkins PV. Factor VIII and von willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010. Jan;16(1):3–13. [PubMed: 19473409]
   PubMed Web of Science ®Google Scholar
• Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020. Sep 10; 383(11):1018–1027. [PubMed: 32905674]
   PubMed Web of Science ®Google Scholar
• Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009. Dec;27(12):1186–1190. [PubMed: 19915550].
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/ B with inhibitors: phase 2 trial results. Blood. 2019. Nov 28; 134(22):1973–1982. [PubMed: 31444162]
   PubMed Web of Science ®Google Scholar
• Patel-Hett S, Martin EJ, Mohammed BM, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019. Sep;25(5):797–806. [PubMed: 31336410].
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017. Aug 31;377(9):819–828. PubMed: 28691885
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011. Dec 22; 365(25):2357–2365. [PubMed: 22149959]
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014. Nov 20; 371(21):1994–2004. [PubMed: 25409372]
   PubMed Web of Science ®Google Scholar
• Butterfield JSS, Hege KM, Herzog RW, et al.A molecular revolution in the treatment of hemophilia. Mol Ther. 2020. Apr 8;28(4):997–1015. [PubMed: 31843450]
   PubMed Web of Science ®Google Scholar
• Pierce GF. Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns. Haemophilia. 2021 Feb;27(3):103–113. [PubMed: 32484283]
   PubMedGoogle Scholar
• Pipe SW. Delivering on the promise of gene therapy for haemophilia. Haemophilia. 2021. Feb;27(3):114–121. [PubMed: 32490590]
   PubMedGoogle Scholar
• Calcedo R, Vandenberghe LH, Gao G, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009. Feb 1;199(3):381–390. [PubMed:19133809]
   PubMed Web of Science ®Google Scholar
• George LA. Hemophilia gene therapy comes of age. Hematology Am Soc Hematol Educ Program. 2017. Dec;8(1):587–594. [PubMed: 29222308]
   Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020. Jan 2; 382(1):29–40. [PubMed: 31893514]
   PubMed Web of Science ®Google Scholar
• Iorio A, Skinner MW, Clearfield E, et al. CoreHEM panel. core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018. Jul;24(4):167–172. [PubMed: 29781145].
   Web of Science ®Google Scholar
• Leavitt AD, Konkle BA, Stine K, et al. Updated follow-up of the alta study, a phase 1/2 study of giroctocogene fitelparvovec (SB-525) gene therapy in adults with severe hemophilia A. Blood. 2020;136(1):12.
   Google Scholar
• Pipe SW, Ferrante F, Reis M, et al. First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A - BAY 2599023 has broad patient eligibility and stable and sustained long-term expression of FVIII. Blood. 2020;136(1):44–45.
   Google Scholar
• Doering CB, Denning G, Shields JE, et al. Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor viii lentiviral vector gene therapy for hemophilia A. Hum Gene Ther. 2018. Oct;29(10):1183–1201. [PubMed: 30160169].
   PubMed Web of Science ®Google Scholar
• Dunbar CE, High KA, Joung JK, et al.Gene therapy comes of age. Science. 2018. Jan 12;359 (6372):4672. [PubMed:2932624 4]
   Web of Science ®Google Scholar
• Ohmori T, Nagao Y, Mizukami H, et al. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep. 2017. Jun 23; 7(1):4159. [PubMed: 28646206]
   PubMedGoogle Scholar
• Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold?. Ther Adv Hematol. 2018 Aug 27;9(9):273–293. [PubMed: 30210756]
   PubMed Web of Science ®Google Scholar
• George LA. Hemophilia gene therapy comes of age. Blood Adv. 2017. Dec 8;1(26):2591–2599. [PubMed: 29296912]
   PubMed Web of Science ®Google Scholar
• Almeida-Porada G, Atala A, Porada CD. In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application. Mol Ther Methods Clin Dev. 2016. Mar 30;5:16020. [PubMed: 27069953]
   PubMedGoogle Scholar
• El-Akabawy N, Rodriguez M, Ramamurthy R, et al. Defining the optimal FVIII transgene for placental cell-based gene therapy to treat hemophilia A. Mol Ther Methods Clin Dev. 2020. Mar 14; 17:465–477. [PubMed:32258210]
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Konkle BA, Croteau SE, et al. First-in-human phase 1/2 clinical trial of SIG-001, an innovative shielded cell therapy platform, for hemophilia Α. Blood. 2020;136(1):8.
   PubMedGoogle Scholar